HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

HZNPUnited States

33 filed reports · 666 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$3.63B

FY2022 · to Dec 31, 2022

up +12.5% vs $3.23B

10-K

Net income

$521M

FY2022 · to Dec 31, 2022

down −2.4% vs $534M

10-K

Operating income

$617M

FY2022 · to Dec 31, 2022

up +13.7% vs $543M

10-K

Latest quarter

Revenue

$945M

Q2 FY2023 · to Jun 30, 2023

up +7.8% vs $876M

10-Q

Net income

$127M

Q2 FY2023 · to Jun 30, 2023

up +108% vs $61M

10-Q

Operating income

$143M

Q2 FY2023 · to Jun 30, 2023

up +61.3% vs $88.6M

10-Q

Filed reports

33 reports · Jun 2015 to Jun 2023

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR254,973Jun 2015 to Jun 2023
Annual · 10-KSEC EDGAR84,683Dec 2015 to Dec 2022

Documents

PeriodTypePeriod endPublishedFactsSource
FY2023 Q210-Q2023-06-302023-08-08432Open
FY2023 Q110-Q2023-03-312023-05-03255Open
FY202210-K2022-12-312023-03-01919Open
FY2022 Q310-Q2022-09-302022-11-02302Open
FY2022 Q210-Q2022-06-302022-08-03192Open
FY2022 Q110-Q2022-03-312022-05-04202Open
FY202110-K2021-12-312022-03-01551Open
FY2021 Q310-Q2021-09-302021-11-03208Open
FY2021 Q210-Q2021-06-302021-08-04181Open
FY2021 Q110-Q2021-03-312021-05-05190Open
FY202010-K2020-12-312021-02-24525Open
FY2020 Q310-Q2020-09-302020-11-02200Open

Financial data

666 concepts · 9,656 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial638 concepts · 8,855 facts · Dec 2013 to Jun 2023

  • Amortization of intangible assets48 · Dec 2013 to Jun 2023
  • Cash and cash equivalents at carrying value48 · Dec 2013 to Jun 2023
  • Comprehensive income net of tax48 · Dec 2013 to Jun 2023
  • Depreciation48 · Dec 2013 to Jun 2023
  • Foreign currency transaction gain loss before tax48 · Dec 2013 to Jun 2023
  • Gross profit (US GAAP)48 · Dec 2013 to Jun 2023
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest48 · Dec 2013 to Jun 2023
  • Income tax expense benefit48 · Dec 2013 to Jun 2023
  • Net income loss48 · Dec 2013 to Jun 2023
  • Nonoperating income expense48 · Dec 2013 to Jun 2023
  • Operating expenses (US GAAP)48 · Dec 2013 to Jun 2023
  • Operating income loss48 · Dec 2013 to Jun 2023
  • Other comprehensive income loss net of tax48 · Dec 2013 to Jun 2023
  • Research and development expense48 · Dec 2013 to Jun 2023
  • Revenue48 · Dec 2013 to Jun 2023
  • Other nonoperating income expense47 · Mar 2014 to Jun 2023
  • Allocated share based compensation expense46 · Dec 2013 to Jun 2023
  • Amortization of financing costs and discounts46 · Dec 2013 to Jun 2023
  • Depreciation depletion and amortization46 · Dec 2013 to Jun 2023
  • Increase decrease in accounts payable46 · Dec 2013 to Jun 2023
  • Increase decrease in accounts receivable46 · Dec 2013 to Jun 2023
  • Increase decrease in deferred income taxes46 · Dec 2013 to Jun 2023
  • Increase decrease in inventories46 · Dec 2013 to Jun 2023
  • Increase decrease in other operating capital net46 · Dec 2013 to Jun 2023

Product15 concepts · 593 facts · Dec 2013 to Jun 2023

  • Revenue533 · Dec 2013 to Jun 2023
  • Inventory Set Up Expense10 · Mar 2021 to Jun 2023
  • Long term purchase commitment amount9 · Dec 2015 to Dec 2017
  • Purchase Order Issued7 · Dec 2015 to Mar 2017
  • Revenue from contracts with customers (excluding tax)7 · Mar 2022 to Jun 2023
  • Business Combination Fair Value Adjustment To Inventory Set Up Expense6 · Jun 2021 to Dec 2022
  • Impairment of intangible assets excluding goodwill5 · Dec 2016 to Mar 2017
  • Milestone Payment Under License Agreement4 · Dec 2021 to Dec 2022
  • Accrued Royalties Assumed2 · Dec 2016
  • Direct operating cost royalty expense2 · Dec 2014 to Dec 2015
  • Impairment Of Acquired In Process Research And Development2 · Dec 2016
  • Long Term Purchase Commitment Reserve Payment2 · Mar 2018 to Sep 2018
  • Royalty Liabilities Assumed2 · Dec 2016
  • Cost of goods sold1 · Dec 2014
  • Revenues1 · Dec 2021

Geography7 concepts · 125 facts · Dec 2013 to Jun 2023

  • Revenue80 · Dec 2013 to Jun 2023
  • Income loss from continuing operations before income taxes foreign11 · Dec 2014 to Dec 2022
  • Current income tax expense benefit10 · Dec 2015 to Dec 2022
  • Deferred income tax expense benefit10 · Dec 2015 to Dec 2022
  • Impairment of leasehold6 · Mar 2021 to Mar 2022
  • Provisions For Income Tax Expense Benefit On Undistributed Earnings Of Subsidiaries6 · Dec 2017 to Dec 2022
  • Number Of Lease Agreements2 · Dec 2015 to Mar 2016

Segment6 concepts · 83 facts · Dec 2016 to Sep 2022

  • Operating income loss71 · Dec 2016 to Sep 2022
  • Goodwill acquired during period5 · Mar 2021 to Dec 2021
  • Goodwill purchase accounting adjustments3 · Sep 2021 to Dec 2021
  • Goodwill period increase decrease2 · Mar 2020
  • Goodwill impairment loss1 · Sep 2022
  • Number Of Marketed Medicines1 · Jun 2018

Segments

801 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or servicesrt:ProductOrServiceAxis21 members · 487 facts

  • UPLIZNA [Member]35 · Mar 2021 to Jun 2023
  • ACTIMMUNE Developed Technology [Member]33 · Dec 2016 to Jun 2023
  • BUPHENYL Developed Technology [Member]33 · Dec 2016 to Jun 2023
  • DUEXIS [Member]33 · Dec 2016 to Jun 2023
  • KRYSTEXXA Developed Technology [Member]33 · Dec 2016 to Jun 2023
  • PENNSAID 2% [Member]33 · Dec 2016 to Jun 2023
  • PROCYSBI [Member]33 · Dec 2016 to Jun 2023
  • QUINSAIR [Member]33 · Dec 2016 to Jun 2023
  • RAVICTI Developed Technology [Member]33 · Dec 2016 to Jun 2023
  • VIMOVO Developed Technology [Member]33 · Dec 2016 to Jun 2023
  • RAYOS [Member]29 · Dec 2016 to Jun 2023
  • Inflammation [Member]24 · Dec 2017 to Sep 2022
  • Orphan Segment Net Sales [Member]19 · Dec 2018 to Sep 2022
  • TEPEZZA [Member]17 · Mar 2020 to Jun 2023
  • MIGERGOT Developed Technology [Member]16 · Dec 2016 to Dec 2019
  • Orphan and Rheumatology [Member]16 · Dec 2016 to Dec 2019
  • Primary Care [Member]12 · Dec 2016 to Mar 2019
  • LODOTRA [Member]11 · Dec 2016 to Dec 2018
  • Legal Proceedings Related to RAYOS [Member]6 · Mar 2017 to Sep 2018
  • T E P E Z Z A Developed Technology4 · Dec 2021 to Dec 2022
  • Teprotumumab [Member]1 · Sep 2018

Product or serviceus-gaap:ProductOrServiceAxis18 members · 106 facts

  • PENNSAID 2% [Member]15 · Dec 2014 to Mar 2018
  • ACTIMMUNE Developed Technology [Member]13 · Dec 2014 to Mar 2018
  • DUEXIS [Member]13 · Dec 2013 to Mar 2018
  • LODOTRA [Member]9 · Dec 2013 to Mar 2018
  • VIMOVO Developed Technology [Member]7 · Dec 2013 to Mar 2018
  • BUPHENYL Developed Technology [Member]6 · Dec 2015 to Mar 2018
  • RAVICTI Developed Technology [Member]6 · Dec 2015 to Mar 2018
  • Legal Proceedings Related to RAYOS [Member]5 · Dec 2015 to Mar 2018
  • PROCYSBI [Member]5 · Dec 2016 to Mar 2018
  • KRYSTEXXA Developed Technology [Member]4 · Dec 2016 to Mar 2018
  • LODOTRA and RAYOS Developed Technology [Member]4 · Dec 2015 to Mar 2017
  • MIGERGOT Developed Technology [Member]4 · Dec 2016 to Mar 2018
  • QUINSAIR [Member]4 · Dec 2016 to Mar 2018
  • RAYOS [Member]4 · Dec 2013 to Dec 2016
  • KRYSTEXXA and MIGERGOT [Member]2 · Dec 2016
  • Teprotumumab [Member]2 · Dec 2017 to Mar 2018
  • VIMOVO intellectual property [Member]2 · Dec 2014 to Dec 2015
  • PROCYSBI and QUINSAIR [Member]1 · Dec 2016

Statement geographicalsrt:StatementGeographicalAxis4 members · 98 facts

  • Rest of World [Member]33 · Dec 2016 to Jun 2023
  • United States [Member]33 · Dec 2016 to Jun 2023
  • Ireland [Member]26 · Dec 2016 to Dec 2022
  • Lake Forest Office [Member]6 · Mar 2021 to Mar 2022

Statement business segments4 members · 83 facts

  • Orphan [Member]28 · Dec 2018 to Sep 2022
  • Inflammation [Member]26 · Dec 2017 to Sep 2022
  • Orphan and Rheumatology [Member]16 · Dec 2016 to Dec 2019
  • Primary Care [Member]13 · Dec 2016 to Mar 2019

Statement geographicalus-gaap:StatementGeographicalAxis4 members · 27 facts

  • Ireland [Member]11 · Dec 2014 to Dec 2017
  • Rest of World [Member]7 · Dec 2013 to Mar 2018
  • United States [Member]7 · Dec 2013 to Mar 2018
  • Lake Forest Office [Member]2 · Dec 2015 to Mar 2016

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY (HZNP) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY (HZNP): FY2022 revenue $3.63B · FactIQ